Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Levetiracetam Sun
Levetiracetam SUN 100 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-213387 · Präparat HOS-155098
In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with
levetiracetam in placebo-controlled and open label extension studies. Sixty of these patients were
treated with levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645
patients have been treated with levetiracetam in placebo-controlled and open label extension studies.
233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these
paediatric age ranges, these data are supplemented with the post-marketing experience of the use of
levetiracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-05T17:50:00Z · SHA-256 f80259f0a633129e975a9f79564d138649ec314b1edc442f788673298850b8fe · Passage fedc1a5f0e0c30ef1fe608375aff0dcee15b729856ff083e7adbddf0844db5ae · Zeichen 8855–9465 im Abschnitt
Nebenwirkungen · Levetiracetam Sun
Levetiracetam SUN 100 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-213388 · Präparat HOS-155098
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety
study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age
with epilepsy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-05T17:50:00Z · SHA-256 f80259f0a633129e975a9f79564d138649ec314b1edc442f788673298850b8fe · Passage 41ed00d104d19c23174963c54848459e44b443ab02b058444d67ba507e1a8f21 · Zeichen 9467–9683 im Abschnitt
Nebenwirkungen · Levetiracetam Sun
Levetiracetam SUN 100 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-213389 · Präparat HOS-155098
The adverse reaction profile of levetiracetam is generally similar across age groups and across the
approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical
studies were consistent with the safety profile of levetiracetam in adults except for behavioural and
psychiatric adverse reactions which were more common in children than in adults. In children and
adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood
swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal
behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other
age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-05T17:50:00Z · SHA-256 f80259f0a633129e975a9f79564d138649ec314b1edc442f788673298850b8fe · Passage f89e26efe61ab6ecadb6148db9f93effffb4503db8b09a1457249510c6315db2 · Zeichen 9685–10470 im Abschnitt
Nebenwirkungen · Levetiracetam Sun
Levetiracetam SUN 100 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10–11
HOS-213390 · Präparat HOS-155098
10
irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more
frequently than in other age groups or in the overall safety profile.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-05T17:50:00Z · SHA-256 f80259f0a633129e975a9f79564d138649ec314b1edc442f788673298850b8fe · Passage 9f14a25194f9f802c7e9e222a1c3168c25b155137f69293da3e34fa6ec3f9143 · Zeichen 10523–10690 im Abschnitt
Nebenwirkungen · Levetiracetam Sun
Levetiracetam SUN 100 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-213391 · Präparat HOS-155098
A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed
the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with
partial onset seizures. It was concluded that levetiracetam was not different (non inferior) from
placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory
Screen Composite score in the per-protocol population. Results related to behavioural and emotional
functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as
measured in a standardized and systematic way using a validated instrument (CBCL – Achenbach
Child Behavior Checklist). However, subjects, who took levetiracetam in the long-term open label
follow-up study, did not experience a worsening, on average, in their behavioural and emotional
functioning; in particular measures of aggressive behavior were not worse than baseline.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-05T17:50:00Z · SHA-256 f80259f0a633129e975a9f79564d138649ec314b1edc442f788673298850b8fe · Passage 3a04aa608c433e29c3bdbd50a0541a7a5b8e7641659815891457a4dabeeaf89a · Zeichen 10692–11654 im Abschnitt
Nebenwirkungen · Levetiracetam Sun
Levetiracetam SUN 100 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-213392 · Präparat HOS-155098
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-05T17:50:00Z · SHA-256 f80259f0a633129e975a9f79564d138649ec314b1edc442f788673298850b8fe · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 11656–12011 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.